The global xerostomia (dry mouth disease) therapeutics market size reached USD 763.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,007.3 Million by 2033, exhibiting a growth rate (CAGR) of 2.98% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 763.0 Million |
Market Forecast in 2033
|
USD 1,007.3 Million |
Market Growth Rate 2025-2033 | 2.98% |
Xerostomia, or dry mouth, refers to symptoms or sensations of oral dryness that are usually caused due to a decrease in the amount of saliva. This condition is triggered by the adverse effects of radioactivity in the neck and head, increasing consumption of antianxiety drugs, dehydration, diabetes, and Alzheimer’s disorder. It can be treated with the support of salivary pens or stimulants, artificial saliva, prescribed medications, and home remedies, including sipping water and moisturizing lips. Apart from this, the early diagnosis of salivary glands by practitioners and the usage of recommended mouth moisturizing products, such as over-the-counter (OTC) rinsing, can assist in lubricating the mouth. These treatments alleviate discomfort, prevent severe complications, fix taste disorders, and mitigate bad breath and taste disorders. Consequently, xerostomia therapeutics are used across several hospitals and clinics to deal with decreased salivary gland function.
The increasing incidences of dry mouth, especially amongst the geriatric population, due to medicine side-effects of radiotherapy and chemotherapy and the rising need for dry mouth relief products are primarily driving the market growth. Additionally, the growing uptake of several prescription-based toothpaste, vitamin gummies, and medicines for treating Sjogren’s syndrome, Alzheimer’s diseases, and human immunodeficiency virus (HIV) that cause xerostomia is acting as another growth-inducing factor. In line with this, the rising consumer awareness regarding the early diagnosis of xerostomia, significant enhancements in healthcare expenditure, and the advent of diverse diagnostic technologies are propelling the market growth. Moreover, the favorable initiatives being commenced by governments to sensitize consumers regarding the xerostomia disease, its symptoms, causes, and treatments are impelling the market growth. Apart from this, the easy availability of various therapeutic drugs and ongoing research and development (R&D) activities are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global xerostomia (dry mouth disease) therapeutics market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on type, drug type and distribution channel.
Breakup by Type:
Breakup by Drug Type:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Biotene (GSK plc), Parnell Pharmaceuticals Inc., Quest Products LLC, Saliwell Ltd, Sun Pharmaceutical Industries Limited and West-Ward Pharmaceutical (Hikma Pharmaceuticals plc).
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Type, Drug Type, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | 3M Company, Biotene (GSK plc), Parnell Pharmaceuticals Inc., Quest Products LLC, Saliwell Ltd, Sun Pharmaceutical Industries Limited, West-Ward Pharmaceutical (Hikma Pharmaceuticals plc). |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global xerostomia (dry mouth disease) therapeutics market was valued at USD 763.0 Million in 2024.
We expect the global xerostomia (dry mouth disease) therapeutics market to exhibit a CAGR of 2.98% during 2025-2033.
The rising incidences of dry mouth disease, along with the growing consumer awareness regarding the early diagnosis of xerostomia, are primarily driving the global xerostomia (dry mouth disease) therapeutics market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective oral treatment procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with healthcare professionals, thereby negatively impacting the global market for xerostomia (dry mouth disease) therapeutics.
Based on the type, the global xerostomia (dry mouth disease) therapeutics market can be categorized into artificial saliva/saliva substitutes and salivary stimulants. Currently, artificial saliva/saliva substitutes account for the majority of the global market share.
Based on the drug type, the global xerostomia (dry mouth disease) therapeutics market has been segregated into OTC and prescription, where OTC currently holds the largest market share.
Based on the distribution channel, the global xerostomia (dry mouth disease) therapeutics market can be bifurcated into hospital pharmacy, retail pharmacy, and online pharmacy. Among these, retail pharmacy exhibits a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global xerostomia (dry mouth disease) therapeutics market include 3M Company, Biotene (GSK plc), Parnell Pharmaceuticals Inc., Quest Products LLC, Saliwell Ltd, Sun Pharmaceutical Industries Limited, and West-Ward Pharmaceutical (Hikma Pharmaceuticals plc).